Anti-CGRP Migraine Antibodies Linked to Higher Miscarriage Risk in Pregnancy Cohort
Start here
At AHS 2026, the AM-PREGNANT cohort linked first-trimester exposure to anti-CGRP monoclonal antibodies — newer migraine preventives — with a higher rate of spontaneous abortion. Drawing on US MarketScan real-world data on more than 7,500 pregnancies in women aged 15 to 45 with chronic migraine before conception, the observational analysis found exposure associated with a roughly 40–45% relative increase in miscarriage risk, with absolute risk rising from single-digit baseline levels. The data cannot establish causation. Propranolol showed no increased risk, consistent with existing guidance to switch to it when planning pregnancy. Clinicians prescribing CGRP agents to women of childbearing potential will need to weigh this signal against the drugs' benefits. Questions still open include whether the drugs directly contribute to pregnancy loss and how prescribers should counsel patients.
Written by a model from the reports · updated 2 hours ago
Developments
- Oct 15 00:00 · 1 reportFirst-trimester anti-CGRP exposure tied to 42% higher miscarriage riskyoutube.com · Anti-CGRP Antibodies Linked to Higher Spontaneous Abortion Risk in AM-PREGNANT Cohort
- Oct 12 23:28 · 1 reportCGRP-targeting drugs show higher miscarriage rate in cohortreddit.com · Newer Migraine Drugs Linked to a 40% Higher Risk of Miscarriage in Pregnant Women, Study Suggests — Study Raises Questions About the Pregnancy Safety of CGRP-Targeting Treatments, but Further Research Is Needed to Determine Whether the Medications Directly Contribute to Pregnancy Loss.
Coverage timeline
Follow the coverage to see the different angles.
- youtube.comAnti-CGRP Antibodies Linked to Higher Spontaneous Abortion Risk in AM-PREGNANT Cohort
First-trimester exposure to anti-CGRP monoclonal antibodies was associated with a 42% higher relative risk of spontaneous abortion in the AM-PREGNANT cohort, with absolute risk rising from about 6% in unexposed women to just under 9%. The cohort drew on US MarketScan real-world data covering more than 7,500 pregnant women aged 15 to 45 with chronic migraine before pregnancy. Propranolol showed no increased risk, consistent with current guidance to switch to it when planning pregnancy.
- reddit.comPickNewer Migraine Drugs Linked to a 40% Higher Risk of Miscarriage in Pregnant Women, Study Suggests — Study Raises Questions About the Pregnancy Safety of CGRP-Targeting Treatments, but Further Research Is Needed to Determine Whether the Medications Directly Contribute to Pregnancy Loss.
CGRP-targeting migraine drugs were associated with a higher miscarriage rate in the AM-PREGNANT cohort released at AHS 2026: roughly 5% in users versus about 2% in non-users, a relative increase of about 45%. The observational cohort covered 7,119 women and 7,579 pregnancies and cannot establish that the drugs cause pregnancy loss. Clinicians prescribing CGRP agents to women of childbearing potential will need to weigh this signal against the drugs' benefits.
Heat trend for this story
Heat now 19·Peak in the comparable set 19 (Oct 18 05:00)·Change over 24h in the comparable set –
The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.